Skip to content
Back to search results

EORTC QLQ-C30

Introduced by
Nico Aaronson et al.
Year
1993
Type
Self-report quality of life questionnaire
Family
Oncology and Cancer Outcomes
Font size

What does it do?

The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients.

Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.

The intuition behind the method

Cancer profoundly disrupts patients' lives across multiple dimensions—physical capacity, emotional well-being, relationships, and ability to work. The QLQ-C30 captures this complexity by measuring five functional scales (physical, emotional, cognitive, social, role), symptom scales (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea), and global health status. Unlike narrow symptom checklists, it reflects what cancer patients themselves identify as important: not just whether a treatment shrinks the tumor, but whether it allows them to function, enjoy life, and pursue meaningful activities. This patient-centered philosophy distinguishes it from clinician-rated toxicity scales.

History

The EORTC QLQ-C30 was developed in 1993 by the EORTC Quality of Life Group, led by Nico Aaronson and colleagues, published in the Journal of the National Cancer Institute. It evolved from earlier EORTC work on quality of life measurement and incorporated input from cancer patients, clinicians, and psychometricians across multiple countries. Version 3.0 (current) was released in 1999. The instrument has since become the gold standard in oncology; a pediatric adaptation (QLQ-C30 Peds) was created for ages 8-18, and 40+ cancer-specific modules (e.g., for lung, breast, colorectal cancer) extend coverage of disease-specific symptoms.

When to use it

The QLQ-C30 is indicated for measuring quality of life in adult cancer patients across all cancer types and disease stages. It is particularly valuable in randomized controlled trials comparing treatments, in clinical practice to monitor patient well-being and guide supportive care decisions, in health economic analyses to evaluate cost-effectiveness, and in observational studies tracking outcomes over time. It is suitable for both curative and palliative contexts. It is less appropriate for very young children (use EORTC QLQ-C30 Peds for ages 8-18) or for non-cancer populations.

Limitations and considerations

  • Modest symptom specificity—does not probe depth into individual symptoms (e.g., pain location, quality, temporal pattern), limiting utility for detailed symptom assessment without supplementary measures
  • Requires literacy—relies on written comprehension; interviewer administration necessary for patients with low literacy or severe cognitive impairment
  • Limited data on clinical cutoffs—while reference ranges exist, specific cutoff scores for intervention thresholds are not universally defined; interpretation relies more on individual and group comparisons than diagnostic cutoffs
  • Not a diagnostic tool—screens and tracks quality of life but does not diagnose depression, anxiety, or other comorbidities; supplementary mental health measures may be needed

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Multidimensional coverage—measures five functional domains and nine symptom dimensions, capturing the full impact of cancer on patients' lives
  • Extensively validated—used in thousands of clinical trials, demonstrating strong psychometric properties (Cronbach's α typically 0.70-0.92 across scales), reliability over time (test-retest r > 0.70), and sensitivity to clinical change
  • Internationally standardized—validated in 80+ languages with translation guidelines, enabling cross-cultural comparisons and global research
  • Free for research—EORTC provides no-cost licensing for academic research and clinical use, with downloadable forms and scoring algorithms
  • Patient-centered—derived from patient interviews and focus groups, ensuring items reflect outcomes that matter to cancer patients themselves

Applications

  • Randomized controlled trials: In a landmark trial comparing chemotherapy regimens for advanced non-small cell lung cancer, the QLQ-C30 was the co-primary endpoint alongside progression-free survival, demonstrating that treatment efficacy must be balanced against quality of life impact (Maemondo et al., 2010, N Engl J Med).
  • Clinical monitoring: Oncology practices use QLQ-C30 results at each follow-up visit to identify patients with declining QoL, triggering palliative care referrals, psychosocial support, or adjustments to supportive medications (e.g., anti-emetics, pain management).
  • Health economic evaluation: A cost-effectiveness analysis of breast cancer survivorship programs used QLQ-C30 data to calculate quality-adjusted life years (QALYs), informing resource allocation decisions (van den Heuvel et al., 2021, Ann Oncol).
  • International outcomes research: A 35-country observational study of colorectal cancer survivors used QLQ-C30 to compare long-term quality of life across healthcare systems, identifying educational and supportive care strategies that sustained functioning in different contexts.

How it works

How it works

1

The QLQ-C30 comprises 30 items, most using a 4-point Likert scale (1=Not at all, 4=Very much), with items on global health using a visual analog scale (1-7). It is self-administered and typically takes 5-10 minutes to complete. Paper, online, and digital versions are available. Validated in 80+ languages and suitable for patients with most cancer types and disease stages.

2

Raw scores are converted to standardized 0-100 scales for each of five functional dimensions (Physical, Role, Emotional, Cognitive, Social Functioning), nine symptom scales (Fatigue, Nausea/Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Difficulty), and one Global Health/Quality of Life scale. Higher functional scores indicate better functioning; higher symptom scores indicate greater symptom burden. Scoring algorithms and an online calculator are provided by EORTC (eortc.org).

3

Global Health/QoL scale: 0-100 (higher = better overall quality of life). Functional scales: 0-100 (higher = better functioning). Symptom scales: 0-100 (higher = greater symptom burden). Clinical significance: changes of ≥10 points on any scale are often considered clinically meaningful. Interpretation depends on cancer type and treatment phase (e.g., acute toxicity during chemotherapy vs. long-term survivorship). Comparison to published reference data from similar patient populations guides contextual interpretation.

Common pitfalls

  • Using global QoL scores alone without examining functional and symptom subscales—a patient may report acceptable overall QoL but suffer significant fatigue or emotional distress, requiring targeted intervention
  • Comparing scores across different cancer types without reference data—QoL profiles vary substantially by cancer site and stage; raw scores alone can be misleading without context-specific normative data
  • Assuming static cutoffs apply universally—clinical significance of a 10-point change depends on baseline severity, treatment phase, and individual patient priorities; one threshold does not fit all scenarios
  • Administering the paper version in settings where burden matters—in fast-paced clinics or very ill patients, electronic self-administration or proxy completion (with appropriate caveats) may improve completion and reduce response burden
  • Ignoring missing data patterns—systematic missing responses on certain items may indicate cognitive decline or emotional distress rather than random error; investigate and document patterns

Frequently asked questions

How do I interpret a 10-point change on the Physical Functioning scale?

A 10-point change is conventionally regarded as clinically meaningful. For example, if a patient's Physical Functioning score improves from 60 to 70 during or after treatment, this suggests a noticeable improvement in their ability to engage in daily activities. However, the clinical relevance depends on context: a 10-point improvement from 20 to 30 indicates recovery from severe limitation but still substantial impairment; a change from 80 to 90 represents modest incremental gain in an already high-functioning patient.

Should I use the QLQ-C30 alone, or do I need cancer-specific modules?

The QLQ-C30 alone provides comprehensive assessment of generic cancer impact. EORTC cancer-specific modules (e.g., QLQ-BR23 for breast cancer, QLQ-LC13 for lung cancer) should be added when you need detailed measurement of disease-specific symptoms or toxicities. Many major trials combine the QLQ-C30 with a relevant module for complete coverage.

Can proxy respondents (family members or clinicians) complete the QLQ-C30 on behalf of patients?

Proxy completion is not recommended as standard practice. Patient self-report is the gold standard because quality of life is inherently subjective. However, in cases of severe cognitive impairment, extreme illness, or imminent death, proxy data may provide valuable information when patient completion is not feasible. Document proxy status in the data and interpret cautiously, as proxies often underestimate patients' quality of life.

Is the QLQ-C30 free to use in my research or clinic?

Yes. The EORTC provides unrestricted, free access to the QLQ-C30 for academic research, quality improvement, and clinical care. You can download the questionnaire, user manual, and scoring algorithms from eortc.org. Commercial use requires licensing; contact EORTC for terms.

Related methods

Sources

  1. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.

    Open DOI reference
    Copied.
  2. Fayers, P. M., & Bottomley, A. (2001). Quality of life research within the EORTC-the EORTC QLQ-C30. European Journal of Cancer, 38(4), 427-431.

    Open DOI reference
    Copied.
  3. Cella, D. (1998). The Functional Assessment of Cancer Therapy Scale: Development and validation. Journal of Clin Oncol, 11(3), 570-579.

    Open publication reference
    Copied.